If you or a loved one is taking Tysabri, understanding the risk factors for progressive multifocal leukoencephalopathy (PML) is essential. The medical community has long emphasized the balance between therapeutic benefit and potential harm, a principle that applies directly to this medication. This guide outlines the key factors that influence PML risk and the monitoring strategies that can help detect early signs.
Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, and the label identifies three factors that increase risk: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These risk factors must be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML is variable but typically includes progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, and visual changes. Diagnosis is confirmed by brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via PCR. Because PML can be rapidly progressive, the label instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such sign (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, adverse event reports submitted to the FDA's FAERS database list PML-related symptoms among the most frequently reported events for Tysabri, including fatigue (19,150 reports), multiple sclerosis relapse (16,691 reports), gait disturbance (9,422 reports), memory impairment (7,895 reports), and cognitive disorder (3,478 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). These reports underscore the challenge of distinguishing PML from multiple sclerosis exacerbations, which can delay diagnosis and treatment.
The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. By blocking lymphocyte adhesion and migration across the blood-brain barrier, Tysabri reduces immune surveillance in the central nervous system. This allows latent JCV, which is present in a majority of the population, to reactivate and infect oligodendrocytes, leading to demyelination and the characteristic lesions of PML. The risk is highest in patients who are anti-JCV antibody positive, have received Tysabri for more than two years, or have a history of immunosuppressant use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label also notes that Tysabri increases the risk of herpes encephalitis and meningitis, with cases reported from a few months to several years after starting therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For patients who develop PML, the prognosis is poor, with most cases resulting in death or severe disability. Because of this risk, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program, which requires patients to read a Medication Guide, understand the risks, and sign an enrollment form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Pharmacies and infusion centers must also be specially certified (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions remain about the adequacy of warnings provided to patients and healthcare providers, particularly regarding the magnitude of PML risk and the need for vigilant monitoring.
From an attorney-related perspective, affected patients in Arizona should be aware of the statute of limitations for filing a product liability or medical malpractice claim. In Arizona, the statute of limitations for personal injury claims is generally two years from the date the injury is discovered or reasonably should have been discovered. For claims involving Tysabri and PML, the timeline between exposure and documented harm is critical. PML can develop months to years after starting Tysabri, and symptoms may initially be mistaken for multiple sclerosis relapse. The date of diagnosis—confirmed by MRI and JCV PCR—typically marks the point at which the injury is discovered. Patients who received Tysabri and later developed PML should consult with an attorney promptly to ensure their claim is filed within the applicable time frame. Evidence of inadequate warnings, such as failure to fully communicate the risk of PML or to ensure patient understanding of the TOUCH program requirements, may support a claim for damages. In summary, Tysabri carries a well-documented risk of PML, a devastating brain infection. The FDA label identifies specific risk factors and mandates monitoring and patient education. However, adverse event reports indicate that PML-related symptoms remain common, and the timeline from exposure to harm can be prolonged. Patients in Arizona who have been harmed by Tysabri-associated PML should seek legal advice promptly to preserve their rights under the state's statute of limitations.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Arizona, the statute of limitations for personal injury claims, including those related to Tysabri and PML, is generally two years from the date the injury is discovered or reasonably should have been discovered. For PML, the date of diagnosis (confirmed by MRI and JCV PCR) typically marks the discovery date. It is crucial to consult an attorney promptly to ensure your claim is filed within this time frame.
The FDA label identifies three key risk factors: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients with these factors are at higher risk and should be monitored closely for any signs of PML.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.